Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with or without Gefitinib in Recurrent or Metastatic Head and Neck Cancer
NCT00088907Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2004
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Aug 2004; status: terminated.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00088907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088907.